Lilly to sell obesity drugs directly on Hims & Hers site

Investing.com · 2026-11-06 13:22 UTC

Lilly to sell obesity drugs directly on Hims & Hers site

By Michael Erman

Nov 6 (Reuters) - Eli Lilly said on Friday it struck a deal to allow Hims & Hers Health to sell obesity drugs Zepbound and Foundayo directly on its platform, sending the telehealth company’s shares up more than 7% in premarket trading.

The Lilly drugs were previously available to patients on Hims & Hers only if they left the site and went to Lilly’s own cash-pay platform LillyDirect.

Read the full story at Investing.com · All coverage of this story